Concepedia

Sergey Shcherbinin

SS

Statistics

Publications

64

Citations

8.8K

H-Index

31

Active since

2008

Affiliations

Eli Lilly (United States)(Current)

University of British Columbia

Indiana University – Purdue University Indianapolis

Indiana University School of Medicine

Eli Lilly (United Kingdom)

Sergey Shcherbinin is an author at Eli Lilly (United States) specializing in medicine, alzheimer disease, and dementia.

Publications per year

2008–2025

64

Publications

64

Donanemab in Early Symptomatic Alzheimer Disease

John R. Sims, Jennifer A. Zimmer, Cynthia Evans et al. · JAMA · 2023 · 2.6K citations · Full text

, , +17

Donanemab in Early Alzheimer’s Disease

Mark A. Mintun, Albert Lo, Cynthia Evans et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

, , +17

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

Elisabeth H. Thijssen, Renaud La Joie, Amy Wolf et al. · Nature Medicine · 2020 · 803 citations · Full text

, , +16

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

Shorena Janelidze, Erik Stomrud, Ruben Smith et al. · Nature Communications · 2020 · 453 citations · Full text

, , +14

Regional profiles of the candidate tau PET ligand <sup>18</sup> F-AV-1451 recapitulate key features of Braak histopathological stages

Adam J. Schwarz, Peng Yu, Bradley B. Miller et al. · Brain · 2016 · 431 citations · Full text

, , +17

1–5 of 64